October 16, 2008
Depomed to Announce Third Quarter 2008 Financial Results on October 30, 2008
Depomed, Inc. (NASDAQ:DEPO) today announced that it will release third quarter financial results for 2008 after the market closes on Thursday, October 30, 2008. The company will webcast a conference call beginning at 5:00 p.m. ET, 2:00 p.m. PT to discuss its results and to provide an update and future outlook on company events.
Interested parties can access the live and archived broadcast of the call at www.depomedinc.com.About Depomed
Depomed, Inc. is a specialty pharmaceutical company with two approved products on the market and other product candidates in its pipeline. The company utilizes its proven, proprietary AcuForm(TM) drug delivery technology to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of AcuForm-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. GLUMETZA(R) (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. Proquin(R) XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is being marketed in the United States within the urology, Ob/Gyn and long-term care specialties by Watson Pharmaceuticals. Product candidate DM-1796 (formerly referred to as Gabapentin GR(R)) is in clinical development for the treatment of neuropathic pain, and product candidate DM-5689 (formerly referred to as Gabapentin GR(R)) is in clinical development for menopausal hot flashes. Additional information about Depomed may be found on its website, www.depomedinc.com.